Mercury Labs — 360° view

Mercury Labs, a company in the Pharmaceuticals industry, reported revenue of ₹19 crore and net profit of ₹0.67 crore for the September 2026 quarter.

Mercury Labs (BSE: MERCURYLAB) closed at ₹748.90 on 20 Nov 2026, down 14.2% over the past year. Its market capitalisation is ₹90 crore and it trades at 26.2 times earnings.

Share price
₹748.90 (20 Nov 2026)
Market cap
₹90 Cr (20 Nov 2026)
P/E
26.20 (20 Nov 2026)
Revenue
₹19 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
12.1% (FY26)
ROE
9.19% (FY26)
Book value
₹489 (FY26)
Dividend yield
0.47% (FY26)
52-week high / low
₹928.50 / ₹620.55 (20 Nov 2026)
1-year return
-14.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: MERCURYLAB

Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.